復宏漢霖(02696.HK)與Eurofarma訂立許可協議,進一步拓展海外市場
格隆匯5月11日丨復宏漢霖(02696.HK)發佈公吿,2022年5月11日,公司與Eurofarma Laboratorios S.A.訂立一份許可協議,據此,公司同意向Eurofarma授出許可,供其於許可地區及人類腫瘤學治療內開發、生產及商業化漢利康® (利妥昔單抗注射液)、漢曲優® (注射用曲妥珠單抗;歐盟商品名:Zercepac®)及漢貝泰® (貝伐珠單抗注射液)(統稱“許可產品”)。本次與Eurofarma訂立許可協議將有助於公司進一步拓展許可產品的海外市場,加強許可產品的可及性和國際影響力。
根據披露,Eurofarma為一家1972年成立的公司,主要於健康產業從事生產和銷售提高人類生活質量的產品和服務,在處方藥、非處方藥、仿製藥、醫院以及腫瘤領域持續創造價值。截至2021年末,Eurofarma擁有700多個產品,僱傭員工超過8,100人。在巴西,其產品和服務覆蓋100多個治療領域,約佔整個處方藥市場的70%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.